Pardes Biosciences to Present at SVB Securities Global Biopharma Conference
Pardes Biosciences (NASDAQ: PRDS) announced participation in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 10:40 a.m. PT / 1:40 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pardes Biosciences (NASDAQ: PRDS) announced participation in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 10:40 a.m. PT / 1:40 p.m. ET. The event will feature discussions about PBI-0451, a novel oral antiviral candidate for COVID-19 treatment and prevention.
Investors can access a live audio webcast on Pardes’ website, with a replay available for 30 days post-event. The company focuses on developing antiviral solutions to address pandemic challenges. For more details, visit their official site for ongoing updates and investor information.
Details
News Market Reaction – PRDS
The recorded move for PRDS in the trading session of this news was +0.48%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of COVID-19, announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 10:40 a.m. PT / 1:40 p.m. ET.
A live audio webcast of the fireside chat will be available in the Investors section of Pardes’ website at www.pardesbio.com, with an archived replay available for 30 days following the event.
About Pardes Biosciences, Inc.
Pardes Biosciences is a clinical-stage biopharmaceutical company created to help solve pandemic-sized problems, starting with COVID-19. We are dedicated to discovering and developing potent and easy-to-prescribe oral antiviral drug candidates so that patients everywhere can get well sooner. For more information, please visit www.pardesbio.com.
Availability of Other Information about Pardes Biosciences
Pardes Biosciences intends to use the Investors page of its website (https://ir.pardesbio.com) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Pardes Biosciences’ Investors website, in addition to following Pardes Biosciences’ press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.
Investor Contacts:
Patrick O'Brien
pobrien@pardesbio.com
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.